Anthropometric and biochemical correlates of PAPP-A2, free IGF-I, and IGFBP-3 in childhood.
Adolescent
Adolescent Development
Anthropometry
Body Height
Body Weight
Child
Child Development
Child, Preschool
Female
Humans
Insulin-Like Growth Factor Binding Protein 3
/ metabolism
Insulin-Like Growth Factor I
/ metabolism
Male
Pregnancy-Associated Plasma Protein-A
/ metabolism
Puberty
/ metabolism
Reference Values
Journal
European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
23
10
2019
accepted:
21
01
2020
pubmed:
22
1
2020
medline:
25
2
2020
entrez:
22
1
2020
Statut:
ppublish
Résumé
Pregnancy-associated plasma protein-A2 (PAPP-A2) is a metalloproteinase that cleaves IGFBP-3 and IGFBP-5. Human mutations in PAPPA2 result in short stature with a low percentage of free IGF-I. Little is known about PAPP-A2 levels and the regulation of free IGF-I throughout childhood. We examined PAPP-A2 and intact IGFBP-3 levels in childhood and explored associations between PAPP-A2, free and total IGF-I, and total and intact IGFBP-3 and their relationship to the percentage of free to total IGF-I and anthropometric factors. Cross-sectional study at a single center. PAPP-A2, free IGF-I, and intact IGFBP-3 levels were measured in childhood (3-18 years old) and an evaluation of the relationship between these proteins and anthropometric factors. In 838 children, PAPP-A2 consistently decreased throughout childhood. In contrast, free IGF-I increased. A pubertal peak in free IGF-I was present in females but was less evident in males. Intact and total IGFBP-3 increased throughout childhood; however, intact IGFBP-3 had a more marked rise than total IGFBP-3. Percent free IGF-I decreased with no distinct pubertal peak. PAPP-A2 levels positively correlated with the percent free IGF-I (Male, Female; r = 0.18, 0.38; P < 0.001) and negatively with intact IGFBP-3 (Male, Female; r = -0.58, -0.65; P < 0.0001). This is the first study to describe serum PAPP-A2 and intact IGFBP-3 in children between 3 and 18 years of age. Our correlative findings suggest that PAPP-A2 is an important regulator of the percent free IGF-I which can be a marker of perturbations in the GH/IGF-I axis.
Identifiants
pubmed: 31961798
doi: 10.1530/EJE-19-0859
pii: EJE-19-0859.R1
pmc: PMC7238294
mid: NIHMS1583389
doi:
pii:
Substances chimiques
IGF1 protein, human
0
IGFBP3 protein, human
0
Insulin-Like Growth Factor Binding Protein 3
0
Insulin-Like Growth Factor I
67763-96-6
PAPPA2 protein, human
EC 3.4.-
Pregnancy-Associated Plasma Protein-A
EC 3.4.24.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
363-374Subventions
Organisme : NICHD NIH HHS
ID : R01 HD078592
Pays : United States
Références
PLoS One. 2011;6(8):e23714
pubmed: 21912604
J Clin Endocrinol Metab. 1997 Jan;82(1):156-8
pubmed: 8989251
J Cell Commun Signal. 2015 Jun;9(2):177-87
pubmed: 25617049
J Biol Chem. 2001 Jun 15;276(24):21849-53
pubmed: 11264294
J Endocrinol. 2009 Sep;202(3):337-45
pubmed: 19474058
Adv Data. 2000 Jun 8;(314):1-27
pubmed: 11183293
J Clin Endocrinol Metab. 2014 May;99(5):1712-21
pubmed: 24606072
J Clin Endocrinol Metab. 1997 Aug;82(8):2497-502
pubmed: 9253324
Eur J Endocrinol. 1996 Feb;134(2):184-9
pubmed: 8630517
Clin Biochem. 2012 Jan;45(1-2):16-21
pubmed: 22032863
J Clin Endocrinol Metab. 1995 Nov;80(11):3284-6
pubmed: 7593439
Int J Pediatr Endocrinol. 2013 Feb 13;2013(1):6
pubmed: 23406437
J Mol Endocrinol. 2018 Jul;61(1):T69-T86
pubmed: 29535161
J Clin Endocrinol Metab. 1994 Mar;78(3):744-52
pubmed: 8126152
Front Endocrinol (Lausanne). 2011 Dec 12;2:95
pubmed: 22654835
J Clin Endocrinol Metab. 2008 Nov;93(11):4210-7
pubmed: 18782877
Sci Rep. 2017 Sep 5;7(1):10455
pubmed: 28874827
Am J Physiol Endocrinol Metab. 2000 Jun;278(6):E967-76
pubmed: 10826997
Endocrinol Jpn. 1992 Dec;39(6):585-91
pubmed: 1284115
Metabolism. 1995 Oct;44(10 Suppl 4):37-44
pubmed: 7476310
J Clin Endocrinol Metab. 2014 May;99(5):1675-86
pubmed: 24483154
J Mol Endocrinol. 2018 Jul;61(1):T11-T28
pubmed: 29255001
EMBO Mol Med. 2016 Mar 31;8(4):363-74
pubmed: 26902202
J Clin Endocrinol Metab. 2005 Nov;90(11):6028-34
pubmed: 16091488
Horm Res. 2001;55(3):115-24
pubmed: 11549872
Clin Pediatr Endocrinol. 2004;13(1):71-8
pubmed: 24790301
Curr Opin Endocrinol Diabetes Obes. 2012 Feb;19(1):47-52
pubmed: 22157400
Genomics. 2015 Jul;106(1):15-22
pubmed: 25817197
Mol Hum Reprod. 2013 Nov;19(11):756-63
pubmed: 23804707
J Pediatr. 2005 Jun;146(6):751-8
pubmed: 15973311
Natl Health Stat Report. 2013 Feb 11;(63):1-3
pubmed: 24992748
Mol Endocrinol. 1997 Jun;11(7):997-1007
pubmed: 9178759
J Clin Endocrinol Metab. 2017 Dec 1;102(12):4568-4577
pubmed: 29029190
J Clin Endocrinol Metab. 1999 Jan;84(1):82-9
pubmed: 9920066
PLoS One. 2011 Feb 28;6(2):e16522
pubmed: 21387019
J Clin Endocrinol Metab. 2009 Aug;94(8):3093-7
pubmed: 19470623
J Mol Endocrinol. 2018 Jul;61(1):T139-T169
pubmed: 29563157
J Clin Endocrinol Metab. 2014 Oct;99(10):E1988-96
pubmed: 24926947
Endocr Rev. 2011 Aug;32(4):472-97
pubmed: 21525302
J Clin Endocrinol Metab. 2000 Nov;85(11):4162-7
pubmed: 11095448
Endocr J. 2012;59(9):771-80
pubmed: 22673406
Horm Res Paediatr. 2016;86(6):361-397
pubmed: 27884013